{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-229610","form_type":"8-K","ticker":"KRRO","cik":"0001703647","company_name":"Korro Bio, Inc.","filed_at":"2026-05-19T11:00:17+00:00","discovered_at":"2026-05-19T11:05:00.245319+00:00","generated_at":"2026-05-19T11:07:37.072985+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Korro Bio selects KRRO-111 for AATD; pre-clinical results show >90% RNA editing","bullets":["KRRO-111 is a GalNAc-conjugated oligonucleotide delivered subcutaneously for AATD.","In vivo editing >90% of SERPINA1 transcript, translating to ~90% repaired functional AAT protein in mouse model.","Repeated dosing nearly eliminated active Z-protein production; pre-existing aggregates progressively cleared.","Company plans to present additional KRRO-111 data at future scientific meeting.","CEO noted well-capitalized position to advance both KRRO-111 and KRRO-121 toward clinical data."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-229610","json":"https://secwatch.observer/filing/0001193125-26-229610.json","markdown":"https://secwatch.observer/filing/0001193125-26-229610.md","text":"https://secwatch.observer/filing/0001193125-26-229610.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703647/000119312526229610/0001193125-26-229610-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703647/000119312526229610/krro-20260519.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T11:07:37.072985+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}